BeOne Medicines (ONC), What Is Behind The Fresh Attention Now?

Simply Wall St.08-19

BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660980444?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-19 16:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660980444","market":"hk","top_or_hot":-1,"title":"BeOne Medicines (ONC), What Is Behind The Fresh Attention Now?","media":"Simply Wall St.","content":"<div>\n<p>BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeOne Medicines (ONC), What Is Behind The Fresh Attention Now?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeOne Medicines (ONC), What Is Behind The Fresh Attention Now?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-19 16:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now","article_id":"2660980444","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/beone-medicines-onc-what-is-behind-the-fresh-attention-now","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660980444","pubTimestamp":1787127890,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month.\nSee our latest analysis for BeOne Medicines.\nFollowing the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","MDCO":"麦迪逊医药","BK4526":"热门中概股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","ONC":"百济神州"},"translate_title":"BeOne Medicines (ONC)，现在新关注的背后是什么？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ONC":1.5},"content_text":"BeOne Medicines (ONC) stock is in focus after the company reported significantly improved second quarter 2026 earnings and raised its full year revenue and GAAP operating income guidance earlier this month. See our latest analysis for BeOne Medicines. Following the earnings beat and raised 2026 guidance, BeOne Medicines stock has picked up momentum, with an 18.31% 1 month share price return and a 19.57% 3 month share price return. That sits alongside an 18.12% 1 year total shareholder return and a very large 3 year total shareholder return that hints at how investors have been reassessing both growth prospects and risk over time. If BeOne Medicines' recent move has you looking at other oncology and biotech opportunities linked to artificial intelligence and data driven drug development, now can be a useful moment to scan 42 healthcare AI stocks After a sharp move on the back of BeOne Medicines' upgraded 2026 outlook, the next consideration is timing. Does it make more sense to accept today’s price, or wait in the hope of a more comfortable entry after the excitement cools? AdvertisementMost Popular Narrative: 10.5% Undervalued The most followed narrative currently places BeOne Medicines' fair value at $412.35 per share, compared with the last close at $369.15. That gap reflects a detailed view on how its oncology portfolio and pipeline could translate into future cash flows using a 7.1% discount rate.  The company's robust pipeline, including multiple late-stage oncology assets (over 20 Phase III trials and >10 proof-of-concept readouts expected in the next 18 months), leverages internal R&D capabilities and the GlueXplorer™ platform to rapidly develop targeted, personalized medicines. This approach is well-aligned with the shift toward precision therapeutics and is presented as supporting long-term earnings and margin expansion as products commercialize.  Read the complete narrative. Curious what sits behind that premium fair value for BeOne Medicines. The narrative leans on ambitious revenue growth, rising profit margins and a higher future earnings multiple. Want to see which specific forecasts and time frames drive that conclusion. Result: Fair Value of $412.35 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, BeOne Medicines still faces concentration risk around BRUKINSA and exposure to tighter U.S. drug pricing, which could pressure margins and challenge the current fair value story. Find out about the key risks to this BeOne Medicines narrative. Another View: What BeOne Medicines’ P/E Is Telling You The earlier fair value estimate points to BeOne Medicines trading at a discount to projected cash flows. The P/E picture looks different. ONC trades on about 64x earnings, compared with roughly 27.4x for peers and a fair ratio of 34.7x. That is a large premium. Is that extra valuation cushion or valuation risk in your view? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:ONC P/E Ratio as at Aug 2026Next Steps If the mix of enthusiasm and caution around BeOne Medicines feels familiar, that is the point. Act while the data is fresh and weigh the 3 key rewards and 1 important warning sign Looking for more investment ideas beyond BeOne Medicines? If you stop with BeOne Medicines, you might miss other stocks that better fit your goals. Put the Simply Wall St Screener to work while this research is fresh.  Target reliable income by scanning for companies built around strong payouts using the 11 dividend fortresses Hunt for quality at a reasonable price with the screener containing 20 high quality undiscovered gems Prioritise resilience and sleep-at-night holdings through the 79 resilient stocks with low risk scores   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BeOne Medicines might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660980444","isCrawlerRequest":true}